Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 17/2009

01-12-2009 | Therapy In Practice

Nail Psoriasis

Clinical Presentation and Best Practice Recommendations

Authors: Dr Felicity Edwards, David de Berker

Published in: Drugs | Issue 17/2009

Login to get access

Abstract

Nail involvement in psoriasis is common and can have a significant impact on quality of life. Manifestations of nail dystrophy in psoriasis include pitting, onycholysis, subungual hyperkeratosis and splinter haemorrhages. Clear evidence regarding the range of treatment options for nail psoriasis is lacking. Topical therapies, including corticosteroids and vitamin D3 analogues, are simple to administer and readily available, but are not effective in treating all types of psoriatic nail dystrophy. Other topical agents have been tried, but may be less readily available. Intralesional corticosteroid injections can be helpful, but may be painful and time consuming. Psoralen plus ultraviolet A treatment has been shown to improve subungual hyperkeratosis, onycholysis, discolouration and nail crumbling, but not pitting. The possibility of future harm with other types of radiation treatment, including superficial radiotherapy and Grenz rays, limits their use. The use of systemic therapies, including the recent introduction of biological agents, is largely restricted to those with concomitant widespread cutaneous or joint involvement because of cost implications and potential toxicity. Further studies regarding the treatment of nail psoriasis are required in order to ascertain the best regimen of therapy for each patient.
Literature
1.
2.
de Jong EMGJ, Seegers BAMPA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1728 patients. Dermatology 1996; 193: 300–3PubMedCrossRef
3.
Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57: 1–27PubMedCrossRef
4.
Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease: a systematic review. J Rheumatol 2006; 33: 1452–6PubMed
5.
deBerker DAR, Baran R, Dawber RPR. The nail in dermatological diseases. In: Baran R, Dawber RPR, de Berker DAR, et al., editors. Baran and Dawber’s diseases of the nails and their management. 3rd ed. Oxford: Blackwell Science, 2001: 172–93CrossRef
6.
Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206–12PubMedCrossRef
7.
Tosti A, Piraccini BM, Cameli N, et al. Calcipotriol in nail psoriasis: a controlled double blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998; 139: 655–9PubMedCrossRef
8.
Rigopoulos D, Ioannides D, Prastitis N, et al. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream [letter]. Acta Dermatol Venereol 2002; 82: 140CrossRef
9.
Frederiksson T. Topically applied fluorouracil in the treatment of psoriatic nails. Arch Dermatol 1974; 110: 735CrossRef
10.
de Jong EM. Dystrophic psoriatic fingernails treated with 1% fluorouracil in a nail penetration-enhancing vehicle: a double-blind study. Dermatology 1999; 199: 313–8PubMedCrossRef
11.
Yamamoto T, Katayama I, Nishioka K. Topical anthralin therapy for refractory nail psoriasis. J Dermatol 1998; 25: 231–3PubMed
12.
Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis 2001; 68: 355–8PubMed
13.
Bianchi L, Soda R, Diluvio L, et al. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study. Br J Dermatol 2003; 149: 1207–9CrossRef
14.
Tosti A, Guerra L, Bardazzi F, et al. Topical ciclosporin in nail psoriasis [letter]. Dermatologica 1990; 180: 110–2PubMedCrossRef
15.
Cannavo SP, Guarneri F, Vaccaro M, et al. Treatment of psoriatic nails with topical cyclosporine: a prospective randomized placebo-controlled study. Dermatology 2003; 206: 153–6PubMedCrossRef
16.
Deffer TA, Goette DK. Distal phalangeal atrophy secondary to topical steroid therapy. Arch Dermatol 1987; 123: 571–2PubMedCrossRef
17.
Wolf R, Tur E, Brenner S. Corticosteroid-induced ‘disappearing digit’. Arch Dermatol 1990; 23: 755–6
18.
Requena L, Zamora E, Martin L, et al. Acroatrophy secondary to longstanding applications of topical steroids. Arch Dermatol 1990; 126: 1013–4PubMedCrossRef
19.
Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol 2008; 88(3): 279–80PubMed
20.
Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% versus clobetasol propionate 0.05% cream: a double-blind study [letter]. Acta Derm Venereol 2007; 87: 167–9PubMedCrossRef
21.
Prins AM, Vos K, Franssen EJ. Instability of topical ciclosporin emulsion for nail psoriasis. Dermatology 2007; 215(4): 362–3PubMedCrossRef
22.
Kalb RE, Bagel J, Korman NJ, et al. Treatment of inter-triginous psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009 Jan; 60(1): 120–4PubMedCrossRef
23.
de Berker DAR, Lawrence CM. A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol 1998; 138: 90–5PubMedCrossRef
24.
Gerstein W. Psoriasis and lichen planus of the nails: treatment with triamcinolone. Arch Dermatol 1962 Oct; 86: 419–21PubMedCrossRef
25.
Abell E, Samman PD. Intradermal triamcinolone acetonide for nail dystrophies. Br J Dermatol 1973; 89: 191–7PubMedCrossRef
26.
Bleeker JJ. Intralesional triamcinolone acetonide using the Port-o-jet and needle injections in localized dermatoses. Br J Dermatol 1974; 91: 479–84CrossRef
27.
Peachey RDG, Pye RJ, Harman RRM. The treatment of psoriatic nail dystrophy with intradermal steroid injections. Br J Dermatol 1976; 95: 75–8PubMedCrossRef
28.
Marx JL, Scher RK. Response of psoriatic nails to oral photochemotherapy. Arch Dermatol 1980; 116: 1023–4PubMedCrossRef
29.
Handfield-Jones SE, Boyle J, Harman RRM. Local PUVA treatment for nail psoriasis. Br J Dermatol 1987; 116: 280–1PubMedCrossRef
30.
Finnerty EF. Successful treatment of psoriasis of the nails. Cutis 1979; 23: 43–4PubMed
31.
Yu RCH, King CM. A double-blind study of superficial radiotherapy in psoriatic nail dystrophy. Acta Dermatol Venereol 1992; 72: 124–36
32.
Lindelof B. Psoriasis of the nails treated with Grenz rays: a double-blind bilateral trial. Acta Dermatol Venereol 1989; 69: 80–2
33.
Kwang TY, Nee TS, Seng KTH. A therapeutic study of nail psoriasis using electron beams [letter]. Acta Dermatol Venereol 1995; 75: 90
34.
Tosti A, Ricotti C, Romanelli P, et al. Evaluation of the efficacy of acitretin for nail psoriasis. Arch Dermatol 2009; 145(3): 269–71PubMedCrossRef
35.
Mahrle G, Schulze HJ, Farber L, et al. Low-dose short term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995; 32: 78–88PubMedCrossRef
36.
Arnold WP, Gerritsen MJP, van de Kerkhof PCM. Response of nail psoriasis to cyclosporine. Br J Dermatol 1993; 129: 750–1PubMedCrossRef
37.
Syuto T, Abe M, Ishibuchi H, et al. Successful treatment of psoriatic nails with low-dose cyclosporine administration [letter]. Eur J Dermatol 2007; 17(3): 248–9PubMed
38.
Feliciani C, Zampetti A, Forleo P, et al. Nail psoriasis: combined therapy with systemic cyclosporine and topical calcipotriol. J Cutan Med Surg 2004; 8: 122–5PubMedCrossRef
39.
Vlachou C, Berth-Jones J. Nail psoriasis improvement in a patient treated with fumaric acid esters. J Dermatol Treat 2007; 18: 175–7CrossRef
40.
41.
Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during one year. J Am Acad Dermatol 2008 Feb; 58(2): 224–31PubMedCrossRef
42.
Rigopoulos D, Gregoriou S, Stratigos A, et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol 2008 Aug; 159(2): 453–6PubMedCrossRef
43.
Hussain W, Coulson I, Owen C. Severe recalcitrant nail psoriasis responding dramatically to infliximab: report of two patients. Clin Exp Dermatol 2008 Jul; 33(4): 520–2PubMedCrossRef
44.
Barrera MV, Habicheyn S, Mendiola MV. Etanercept in the treatment and retreatment of psoriasis in daily practice. Eur J Dermatol 2008; 18(6); 683–7PubMed
45.
Efficacy and safety results from the randomized controlled comparative study of adalimumab versus placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158(3): 558–66
46.
Ko JM, Gottileb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat 2008 Oct; 16: 1–8
47.
Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005 Aug; 52(8): 2513–8PubMedCrossRef
48.
Lamerson C, Stevens G, Sax K. Treatment of nail psoriasis with efalizumab: a preliminary study. Cutis 2008 Sep; 82(3): 217–20PubMed
49.
Korver JEM, Langewouters AMG, Van de Kerkhof PCM, et al. Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 1252–5PubMedCrossRef
50.
Noiles K, Vender R. Nail psoriasis and biologics. J Cutan Med Surg 2009; 13(1): 1–5PubMed
Metadata
Title
Nail Psoriasis
Clinical Presentation and Best Practice Recommendations
Authors
Dr Felicity Edwards
David de Berker
Publication date
01-12-2009
Publisher
Springer International Publishing
Published in
Drugs / Issue 17/2009
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11318180-000000000-00000

Other articles of this Issue 17/2009

Drugs 17/2009 Go to the issue

Review Article

Valsartan

Adis Drug Evaluation

Eprosartan

Therapy In Practice

Acute Severe Asthma

Review Article

Diuretics in Heart Failure

Adis Drug Evaluation

Azacitidine

Review Article

Current and Emerging Treatments for Chronic Lymphocytic Leukaemia